New data shows three triple-combination regimens are "highly effective" for up to 90 percent of cystic fibrosis patients.In what medical researchers are calling a first but very important step for three-drug modulator studies in patients with cystic fibrosis, Vertex Pharmaceuticals Incorporated recently announced positive data from Phase I and Phase 2 studies of three different triple-combination regimens in people with CF, and evaluated two groups of patients — those who have one F508del gene mutation and a second minimal function mutation (F508del/Min) and those with two copies of the F508del mutation.

The data shows approximately 90 percent of those with CF could potentially be positively impacted by these new treatments. 

UAB Departments of Medicine and Pediatrics — both part of the School of Medicine, along with UAB Hospital and Children’s of Alabama, support UAB’s Adult Cystic Fibrosis Program and the Pediatric Cystic Fibrosis Program. The program is accredited by the Cystic Fibrosis Foundation and currently cares for more than 450 individuals with CF. 

The Gregory Fleming James Cystic Fibrosis Research Center and the adult and pediatric CF programs are integrated with the UAB CF clinical trials unit, co-led by said Steven Rowe, M.D., director of the UAB Gregory Fleming James Cystic Fibrosis Research Center, and Isabel Virella Lowell, M.D., an associate professor of pediatric pulmonology and sleep medicine. The center is recognized internationally for its transformative clinical and basic research, including the development of new therapies for the treatment of this devastating disease.

Read the story on UAB News.